Many lung cancer cell lines are resistant to the growth inhibitory eects of retinoids. However, some small-cell lung cancer cell lines were inhibited by all trans-retinoic acid (ATRA) in serum-free medium. We compared the responses of seven non-small cell lung cancer (NSCLC) cell lines to ATRA in serum-free medium and in medium supplemented with delipidized serum. Whereas the growth of four cell lines was inhibited more in serumfree medium, the growth of the Calu-1 cell line was stimulated by ATRA in a dose-dependent fashion with a maximum at 10 78 M. Delipidized serum (42.5%) but not bovine serum albumin (0.15%) suppressed growth stimulation by ATRA. Transcripts of RA receptors RARa and RARg but not of RARb were detected in Calu-1 cells. Receptor expression, the formation of a complex among receptors and a RA-responsive element (RARE), and the transcriptional activation RARE were not suppressed by serum. Natural retinoids and synthetic receptor class-or subtype-selective retinoid agonists, which activated RARs and RXRs for gene transcription from a RARE, and a RAR antagonist (CD2366), which was unable to do so, stimulated the growth of Calu-1 cells in serum-free medium but not in serum-containing medium. Both ATRA and CD2366 enhanced the transcriptional activation of an Activator Protein-1 (AP-1)-luciferase reporter construct in serum-free medium but not in delipidized serum. Transcriptional activation of the RARE by ATRA occurred both in the presence or absence of delipidized serum. These results demonstrate that retinoid-induced growth stimulation of Calu-1 cells is associated with enhanced AP-1 transactivation but not with RARE transactivation.
Introduction
All-trans-retinoic acid (ATRA) and its analogs have shown promising clinical activities in cancer chemoprevention and therapy (Hong et al., 1995; Lotan, 1996) . The presumed mechanisms underlying these eects of retinoids involve modulation of cell growth, dierentiation, and apoptosis (Gudas et al., 1994; Jetten et al., 1992; Lotan, 1995 Lotan, , 1996 . Retinoids are thought to exert their eects by binding to and activation of two classes of nuclear retinoid receptors, the RA receptors (RARs) and the retinoid X receptors (RXRs), which belong to the steroid/thyroid hormone nuclear receptor superfamily. Both receptor classes are encoded by three distinct genes designated a, b and g and function as ligand-activated factors that regulate the transcription of target genes by forming RXR-RAR heterodimers and RXR-RXR homodimers that bind to speci®c RA response elements (RAREs) (reviewed by Mangelsdorf et al., 1994; Pfahl et al., 1994; Chambon, 1996) . Activation of gene expression by retinoid receptors usually involves formation of RXR-RAR heterodimers, their binding to a direct repeat 5 (DR5) type RARE [PuG(G/T)TCA(N) 5 G(G/ T)TCA], and activation of gene transcription (Chambon, 1996) . Nuclear receptors have been implicated in the modulation of cell growth and dierentiation by retinoids on the basis of receptor knockout experiments using homologous recombination (Boylan et al., 1993 (Boylan et al., , 1995 Cliord et al., 1996) , transfection of antisense expression vectors (Oridate et al., 1996) , and enforced expression of transfected receptor cDNAs (Oridate et al., 1996; Houle et al., 1993; Moasser et al., 1995; Robertson et al., 1992 Liu et al., 1996 Soprano et al., 1996) .
Many human small-cell lung cancer (SCLC) cell lines and non-small cell lung cancer (NSCLC) cell lines exhibit resistance to growth inhibition by ATRA (Geradts et al., 1993) and the growth of two of fifteen of these cell lines was even stimulated by ATRA (Geradts et al., 1993) . Assays for growth inhibition were usually carried out in medium supplemented with 10% fetal bovine serum (FBS), which contains various growth factors (e.g. epidermal growth factor, plateletderived growth factor, transforming growth factors a and b). These and other factors that can modulate cell proliferation both positively and negatively may mask or modulate the eect of a test compound such as ATRA. Indeed, it has been reported that growth inhibition of two SCLC cell lines by 13-cis-RA was enhanced in serum-free medium compared to growth in the presence of serum (Avis et al., 1995) . This observation has prompted us to compare and contrast the responses of seven NSCLC cell lines to ATRA in serum-free and serum-containing medium. Furthermore, the serum that we used was delipidized to minimize the eects of serum retinoids and vitamin D on the growth of the cells. In this study, we found that several cell lines that were resistant to growth inhibition by ATRA in medium supplemented with serum, became sensitive in serum-free medium. Surprisingly, the growth of one of the cell lines, Calu-1, was actually stimulated by ATRA treatment in serum-free medium. This growth stimulation was reversed by supplementing the culture medium with delipidized serum but not with serum albumin. We then examined the eects of various natural and synthetic retinoids and explored the signaling pathways involved in the growth stimulatory eects. Our results implicate enhanced transactivation of AP-1 and exclude the transactivation of nuclear retinoid receptors in the growth stimulatory eect of retinoids on Calu-1 cells in serum-free medium.
Results
Eects of ATRA on the growth of human NSCLC cell lines in serum-free and serum-containing medium Among the seven NSCLC cell lines examined for their growth response to ATRA, H322a and Calu-1 cells were resistant to growth inhibition in delipidized serum whereas the other ®ve exhibited a 20 ± 50% inhibition at the highest ATRA concentration (10 76 M) (Figures 1  and 2 ). In serum-free medium, the sensitivity to ATRA was enhanced in four of the cell lines that showed some inhibitory response in serum-containing medium (e.g. H292G, H358, H157 and H1792) (Figure 1 ). H322a cells, which were resistant in serum-containing medium, were also resistant in serum-free medium. Interestingly, H226a cells were slightly stimulated at 10 79 and 10
ATRA, but inhibited at higher concentrations ( Figure  1 ). The Calu-1 cells were growth stimulated by more than twofold in serum-free medium (Figure 2a ). The stimulatory eect was observed at 10 79 to 10 77 M ATRA with a maximum at 10 78 M and a decline at 10 76 M (Figure 2a ). Delipidized serum 42.5% but not 51%, inhibited the growth stimulatory eects of ATRA ( Figure 2c ). Under physiological conditions, ATRA in plasma is bound to serum albumin. Whereas this binding can restrict ATRA's bioavailability to cultured SCLC cells (Avis et al., 1995) it can protect ATRA from being metabolized to polar (inactive) metabolites and provides a controlled delivery of ATRA from the medium to the cells (Hodam and Creek, 1996) . Because normal FBS contains about 3% serum albumin and the 5% FBS in the culture medium prevented growth stimulation by ATRA (Figure 2c) , we examined the eect of 0.15% serum albumin in the medium on the response of Calu-1 cells to ATRA. In contrast to 5% delipidized serum, 0.15% fatty acid-free serum albumin, which can bind ATRA in hydrophobic pockets, or fatty acid-containing albumin, which presumably can bind less ATRA because of bound fatty acids, did not reverse the growth stimulatory eect of 10 78 or 10 77 M ATRA (Figure 2b ).
Expression of nuclear retinoic acid receptors in Calu-1 cells grown in serum-free or serum-containing medium in the absence or presence of ATRA Vitamin A de®ciency in the rat has been found to lead to a 30% increase in the level of RARa, but 80% and 50% decreases in the levels of RARb and RARg, respectively, in both lung and trachea (Verma et al., 1992) . ATRA supplementation of a vitamin A-de®cient diet increased RARb and RARg levels by two-and 11-fold, respectively, whereas the level of RARa remained unchanged (Haq et al., 1991a, b) . Therefore, we analysed the expression of retinoid receptors in Calu-1 cells grown in serum-free and delipidized serum without and with ATRA supplementation. RARa and RARg, were detected by Northern blotting but no RARb was detected. Neither ATRA nor the presence of serum aected the levels of RAR transcripts ( Figure  3 ). (Figure 5a ). The fold activation of transcription was almost identical in cells treated with 10 78 M ATRA in serum-free or serumcontaining medium (Figure 5b ). There results indicate that the ability of nuclear retinoid receptors to bind and transactivate the RARb2 RARE was not compromised by delipidized serum. Moreover, the ®nding that activation of RARb2 RARE occurred in both serumfree and serum-containing medium, whereas growth stimulation occurred only in serum-free medium suggested that enhanced transcription of the RARb2 RARE was either not required or not sucient for growth stimulation by ATRA. Serum-free 10% delipidized Figure 4 Comparison of RARE-speci®c binding activity of nuclear proteins extracted from Calu-1 cells grown in serum-free medium or medium supplemented with 10% delipidized serum. Nuclear extracts were incubated with 32 P-labeled RARE and then analysed by gel-shift and supershift assays as described in Materials and methods Duester, 1996) . ATRA is also isomerized in cells to 13-cis-RA and 9-cis-RA. Therefore, we compared the ability of these natural retinoids to enhance the growth of Calu-1 cells in serum-free medium. In addition to ATRA, retinol, retinal, 9-cis-RA, and 13-cis-RA stimulated Calu-1 cell growth in serum-free medium with an optimum at 10 78 M but had no eect on cell growth in the presence of delipidized serum ( Figure 6 , upper 5 panels). ATRA was most potent, exhibiting considerable activity at 10 79 M. If nuclear receptors are involved in growth stimulation, then the reason for the lower activity of 13-cis-RA at 10
79 M compared to ATRA may be due to the need for 13-cis-RA, which does not bind to RARs, to be isomerized to ATRA (Kojima et al., 1994) . The lower potency of 10 79 M 9-cis-RA relative to ATRA is not clear because the 9-cis isomer has a similar binding anity for RARs as ATRA does and in addition, it can bind RXRs (Chambon, 1996) .
To identify nuclear receptors that may mediate the growth stimulatory eects of retinoids, we analysed the eects of synthetic retinoids, which possess distinct preferences for binding and transactivation of speci®c receptor types (i.e. RARs or RXRs) or subtypes (i.e. a, b, or g), on the growth of Calu-1 cells in serum-free and serum-containing medium. Retinoids selective for RARa (Am80), RARg (CD2325 and SR11363), and RARb/g (TTNN and SR3985) stimulated Calu-1 cell growth in serum-free medium, albeit with dierent potencies ( Figure 6 , middle 5 panels). Am80 was the least potent and SR3985 was the most potent among these retinoids.
Although capable of stimulating growth at lower concentrations, both CD2325 (at 10 77 M and 10
and to a lesser extent SR11363 (at 10 76 M) inhibited growth in serum-free medium, whereas they had no inhibitory eect at these concentrations in serumcontaining medium ( Figure 6 ).
To assess the role of RXRs in the growth stimulatory eects of retinoids, we analysed the eects of RXRselective retinoids on the growth of the Calu-1 cells.
LG1069, SR11217, and SR11234 stimulated the growth of Calu-1 cells to varying degrees (Figure 6 , three lower panels on the left). SR11234 was the poorest stimulator of growth at 10 78 and 10 77 M and inhibited growth at 10 76 M in serum-free medium, as did LG1069.
LG1069 was a potent stimulator at lower concentrations but inhibited growth at 10 76 M. SR11217 exhibited an intermediate potency at 10 78 M but was the most potent stimulator at 10 77 M and showed activity even at 10 76 M ( Figure 6 ). It is noteworthy that at the concentrations that they stimulated the growth of Calu-1 cells, both
LG1069 and SR11217 were reported to exhibit less than 10% transactivation of RARs (Gottardis et al., 1996; Lehmann et al., 1992) , suggesting that RXRs may be involved in growth stimulation even without the involvement of RARs. The retinoid SR11238, which failed to transactivate RARs or RXRs but was reported to exhibit anti-AP-1 activity on a collagenase promoter-reporter construct and inhibit the growth of another NSCLC cell line, Calu-6 , had no eect on the growth of Calu-1 cells in either serum-free or serum-containing medium ( Figure 6 , lower panels, second from right). The activity pro®les of these retinoids suggest that both RARg and RXRs are involved in mediating the stimulation of Calu-1 growth by retinoids, although a role for RARa cannot be excluded.
CD437, a RARg-selective retinoid, and N-(4-hydroxyphenyl)retinamide (4HPR), which does not bind directly to any retinoid receptor but was reported to transactivate a RARE by means of RARs, especially RARg (Kazmi et al., 1996; Fanjul et al., 1996) , exhibited no stimulatory activity on Calu-1 cells in serum-free medium, but inhibited growth eectively. They also inhibited growth in serum-containing medium, but to a lesser extent ( Figure 6 , the lowest panel on the right). Both of these retinoids have been reported to induce apoptosis of cancer cells by a retinoid receptor-independent pathway Shao et al., 1995) . We found that at the higher concentrations both induced apoptosis in Calu-1 cells (data not shown).
Stimulatory eect of a RAR antagonist CD2366 on the growth of Calu-1 cells in serum-free medium
If retinoid receptors are involved in growth stimulation by activating transcription from a RARE, then a retinoid antagonist that binds to receptors but fails to transactivate transcription from RARE should not stimulate by itself and could antagonize stimulation by ATRA. However, as shown in Figure 7 , the antagonist CD2366 stimulated growth in serum-free medium. CD2366 was less potent than ATRA in that 10 76 M was required for growth stimulation, however, the maximal stimulation by CD2366 was at least as high as that by ATRA (Figure 7) . The combination of a marginally stimulatory concentration of CD2366 (10 77 M) with dierent concentrations of ATRA showed no antagonistic eect on ATRA's ability to stimulate growth and the combination of the eective concentration of CD2366 (10 76 M) with dierent ATRA concentrations showed no additive eects on growth stimulation at ATRA doses up to 10 77 M (Figure 7) . The combination of 10 76 M ATRA with 10 76 M CD2366 was less eective in stimulating growth than 10 76 M CD2366 alone. CD2366 antagonized RARE transactivation by ATRA in the Calu-1 cells. ATRA (10 78 M) transactivated RARE-TK-LUC in serum-free medium, whereas CD2366 (10 76 M) failed to do so and antagonized ATRA (Figure 8a) . Similar results were observed in serumcontaining medium (Figure 8b ). These data indicate that serum did not aect RARE transactivation (as in Figure  5 ) and that CD2366 indeed acted as an antagonist of RARE transactivation by ATRA in Calu-1 cells. Thus, because the growth stimulatory eect of CD2366 is clearly dissociated from transactivation of RARE, growth stimulation by ATRA may also be independent of this transactivation.
The stimulatory eect of ATRA on the growth of Calu-1 cells in serum-free medium correlates positively with the transactivation of AP-1 but not RARE Cell proliferation, dierentiation, and transformation are regulated by various transcription factors including AP-1, a complex comprised of dimers of members of the Jun and Fos family of DNA-binding protooncogenes (Angel and Karin, 1991) . These dimers bind to a speci®c DNA sequence (TGAGT-CA) designated as a 12-O-tetradecanoylphorbol-13- Comparison of the ability of ATRA and CD2366 to modulate the transactivation of RARE and AP-1 in Calu-1 cells grown in serum-free and serum-containing medium. Cells were transfected with reporter genes as described in the legend of Figure 5 except that here some cells were also transfected with AP-1-TK-LUC. The cells were then treated with DMSO (control), ATRA (10 78 M), CD2366 (10 76 M), or combinations of ATRA and CD2366 in serum-free medium or in medium supplemented with 5% delipidized serum. The cells were harvested after 18 h and analysed for luciferase activity. The normalized activity in cells transfected with TK-LUC and treated with DMSO was set as 1 in both of serum-free and delipidized serum groups. The activation of TK-LUC in the presence of serum was about twofold higher than in serum-free medium. The results are the mean+s.d. of triplicates acetate (TPA)-responsive element or TRE to either transactivate or transrepress the transcription of downstream genes (Angel and Karin, 1991) . Several studies have shown that certain retinoids, including ATRA, antagonize AP-1 and this eect was related to the growth inhibitory potency of the retinoids (Pfahl, 1993; Salbert et al., 1993; Fanjul et al., 1994; Soprano et al., 1996; Oridate et al., 1996) . Because increased AP-1 activity has been related to growth stimulation in many types of cell, we examined the possibility that the growth stimulatory eect of ATRA and CD2366 on Calu-1 cells is related to their enhancement of AP-1 activity. Calu-1 cells were transiently transfected with a plasmid in which the expression of the luciferase reporter gene is controlled by a fragment of the collagenase gene promoter, which contains an AP-1 consensus sequence. The cells were treated with ATRA or CD2366 in serum-free or serum-containing medium. Both ATRA (10 78 M) and CD2366 (10 76 M) stimulated AP-1 transactivation when added alone or in combination in serum-free medium (Figure 8c ) but not in delipidized serumcontaining medium (Figure 8d ). Neither ATRA nor CD2366 enhanced the transcription of luciferase when cells were transiently transfected with a plasmid containing a mutated AP-1 binding site (TGCTCCA). CD2366 did not antagonize AP-1 transactivation by ATRA. These results show that the ability of ATRA and CD2366 to activate AP-1 is associated with growth stimulation, whereas activation of RARE is not. ATRA (10 78 and 10 76 M) failed to aect AP-1 transactivation in H157 cells, which are not growth stimulated but rather inhibited by ATRA in serum-free medium (data not shown).
To begin to understand how ATRA might stimulate AP-1 activity, we analysed the formation of a complex between AP-1 and the TRE by gel-shift analysis. A single shifted band was formed by incubation of nuclear extracts with 32 P-labeled TRE (Figure 9 ). The identity of the components of this band are not known at this time. They may include several members of the fos/fra/jun family as well as members of the CREB and ATF family, which can form heterodimetic complexes with jun family members. The intensity of the band formed by extracts of cells grown in serum-free medium was one-fourth that of cells grown in medium containing delipidized serum. ATRA decreased the intensity of the band by 30% and 50% in serum-free and serum-containing medium, respectively.
Discussion
We have demonstrated that several retinoids can stimulate the growth of Calu-1 cells in serum-free medium and obtained data that support a mechanism in which liganded retinoid receptors enhance AP-1 activity and thereby stimulate growth. This was an unexpected ®nding because retinoids inhibit the growth of a variety of malignant cell lines (Amos and Lotan, 1991; Gudas et al., 1994; Lotan, 1995) , and we showed that several other NSCLC cell lines were more sensitive to ATRA in serum-free than in serum-containing medium. Similar to our ®nding, the growth of normal human tracheobronchial epithelial cells (Lechner et al., 1982; Wu et al., 1990) and of human lung adenocarcinoma cells (Yang et al., 1992) was enhanced by low ATRA concentrations (510
yet inhibited at high concentrations (10 76 M) (Wu et al., 1990; Geradts et al., 1993) . The growth of SCLC cell lines was inhibited by 13-cis-RA concentrations 410 76 M in serum-free medium but not in the presence of serum and 2% bovine serum albumin (BSA), which was identi®ed as the major serum component responsible for binding radiolabeled ATRA, reversed the growth inhibitory eect of 13-cis-RA (Avis et al., 1995). In our study, 0.15% BSA failed to reverse the stimulatory eect of ATRA on Calu-1 cells, whereas 42.5% serum did reverse the eect. Thus, delipidized serum contains factors other than BSA that suppress growth stimulation by ATRA. It is interesting to note an analogy between our ®ndings and a previous study in which the protein kinase C activator TPA stimulated the growth of two lung carcinoma cell lines in serumfree medium, whereas 1% serum reversed the eect of TPA to growth inhibition (Sanchez et al., 1987) . The enhancement of protein kinase C by ATRA (Kurie et al., 1993) may lead to growth stimulation.
Our results show that the ability of ATRA to stimulate growth in serum-free medium cannot be explained on the basis of changes in receptor levels or transcriptional activation of RARE. Of note is the report that dierentiation of F9 embryonal carcinoma cells can be induced by ATRA by a mechanism that does not require receptor-mediated transactivation of RARE (Kitabayashi et al., 1994) .
Most of several natural and synthetic retinoids including receptor-selective retinoids and a retinoid antagonist stimulated the growth of Calu-1 cells in serum-free medium. Retinol and retinal were somewhat less eective than ATRA at 10 79 M. Among the receptor-selective retinoids, RARa-selective Am80 was the least potent, whereas the RARg-and RARb/gselective retinoids showed higher eciency which decreased in the following order: SR39854 SR113634TTNN4CD2325. Among the RXR-selective retinoids, activity decreased in the following order:
LG10694SR112174SR11234. Interestingly, transfection of RXR into ovarian carcinoma cells restored AP-1 repression and growth inhibition by retinoids (Soprano et al., 1996) , suggesting that RXRs may mediate both suppression and enhancement of growth Comparison of the formation of an AP-1 complex with TRE and its modulation by ATRA in serum-free and serumcontaining medium. Cells were treated with DMSO (control) or ATRA (10 78 M) for 5 days in serum-free medium or medium supplemented with 5% delipidized serum. The cells were then harvested, nuclear proteins were extracted from them and incubated with 32 P-labeled TRE. The formation of an AP-1 complex with TRE was then analysed by gel-shift as described in Materials and methods depending on the cell type. SR11238, which is reported to have anti-AP-1 activity , failed to aect the growth of Calu-1 cells in either serum-free or serum-containing medium. Two other retinoids, CD437 and 4HPR, also failed to stimulate Calu-1 growth. These retinoids induced apoptosis in many cancer cell types including Calu-1 cells by a pathway that appears to be independent of retinoid receptors and AP-1 modulation Shao et al., 1995; Oridate et al., 1996) . Our ®ndings suggest that most retinoids that stimulate cell growth must bind to RARs or RXRs (or metabolism or isomerization to retinoids that can bind in the case of natural retinoids) but do not have to induce transcription via RARE.
A surprising ®nding was the ability of the antagonist CD2366, which binds to all RARs but does not activate transcription of RARE, to stimulate the growth of Calu-1 cells. In Calu-1 cells growth in serum-free medium CD2366 antagonized transcriptional activation by ATRA of transfected RARb2 RARE-TK-LUC. CD2366 alone at 10 76 M stimulated cell growth and at 10 77 M did not antagonize growth stimulation by 10 79 to 10 77 M ATRA. These results suggest that at their optimal concentrations ATRA and CD2366 may be acting by a similar mechanism, which may involve binding to the receptors and recruitment of cofactors to the complex such that a putative autocrine growth signaling pathway is enhanced. The reason for the apparent antagonism of CD2366's stimulatory action by high doses of ATRA may re¯ect the higher anity of ATRA for binding to RARs, which could result in displacing CD2366 from the ligand-binding site.
A precedent for ligand-dependent activity of retinoid receptors that does not require receptor-DNA interaction and is independent of transcriptional activation of RARE is antagonism of AP-1 activity (Nicholson et al., 1990; Schule et al., 1991; Pfahl, 1993) . This antagonism was attributed to weak protein-protein interactions between RARs or RXRs and c-Jun and c-Fos (Schule et al., 1991; Pfahl, 1993) , as well as to competition for the co-factor protein CBP (Kamei et al., 1996) . This antagonism has been implicated in the growth suppressive eects of retinoids in some tumor cells (Pfahl, 1993; Salbert et al, 1993; Fanjul et al., 1994; Chen et al., 1995; Soprano et al., 1996; Oridate et al., 1996) . Using Calu-1 cells in serum-free medium, we obtained the exact opposite result because ATRA enhanced AP-1 activation and stimulated cell growth. Nonetheless, our results are in agreement with reports that ATRA and other retinoids can act synergistically with TPA, the classical activator of AP-1, to enhance HL-60 cell dierentiation (Zylber-Katz et al., 1986 ) and the proliferation of human skin ®broblasts (Zhang et al., 1992) . Mechanistically, our results are similar to reports that the intact estrogen receptor, or its ligandbinding domain, stimulated transactivation of an AP-1 like sequence in the ovalbumin gene promoter or an authentic AP-1 sequence by c-Jun and c-Fos in chick embryo ®broblasts (Gaub et al., 1990) . Moreover, the mutated thyroid hormone receptor c-erbA and the viral oncogene v-erbA stimulated AP-1 activity in HeLa cells (Sharif and Privalsky, 1991) . The dierence between suppression of AP-1 in some cells and activation in others may re¯ect dierences in cell-type speci®c factors (Zhang et al., 1991; Pfahl, 1993) .
The enhanced transactivation of AP-1 in Calu-1 cells treated with ATRA in serum-free medium was not due to increased binding of AP-1 to DNA as indicated by gel-shift analyses. Furthermore, the absence of AP-1 transactivation by ATRA in serum-containing medium cannot be explained by the 50% decrease in the amount of AP-1-DNA complex because this amount is still much higher than that in cells grown in serumfree medium where transactivation was enhanced. Our ®ndings with Calu-1 cells are distinct from those in F9 embryonal carcinoma cells, where ATRA increased AP-1 by inducing c-jun transcription (Kitabayashi et al., 1994) . At the present time, we do not know the mechanism by which ATRA stimulates AP-1 transactivation. However, the activation of AP-1 appears to be associated with growth stimulation because both ATRA and CD2366 increased AP-1 and stimulated growth only in serum-free and not in serum-containing medium.
It is not clear what factors in the serum neutralize the stimulatory eects of ATRA and CD2366 on AP-1 activity and on growth. It is possible that in cells grown in the presence of serum, growth factors and mitogens induce immediate-early genes including c-fos (Lamph et al., 1988) , as indicated in our cell system by the greater amount of AP-1-TRE complex in cells grown in the presence of serum compared to cells grown under serum-free conditions (Figure 9 ). Cells already growth stimulated by serum may not be able to be stimulated further by ATRA. In contrast, cells grown in serum-free medium, without exogenous mitogens may respond to the mitogenic eects of ATRA. Others have demonstrated that ATRA and other retinoids can enhance the growth of synovial ®broblasts (Gitter et al., 1991) and T-cells (Jiang et al., 1992) by potentiating the eects of interleukin-1, interleukin-2 and ®broblast growth factor. We speculate that ATRA may enhance the eects of autocrine factors in Calu-1 cells growth in serum-free medium without exogenous factors.
Because some of the retinoids that stimulate Calu-1 cell growth are being evaluated in clinical trials, the question arises as to whether our ®ndings have clinical implications. This question cannot be answered directly by our studies because the growth stimulatory eect was noted only in serum-free and not in serum containing medium. Recently, two major clinical trials that used either b-carotene and a-tocopherol (The ATB Cancer Prevention Study Group, 1994) or b-carotene and retinol (Omenn et al., 1996) reported unexpected increases in the incidence of lung cancer, especially among current smokers. Although no increases were noted in ATRA levels in the plasma of individuals treated with b-carotene, it cannot be excluded that bcarotene may be converted to ATRA in some premalignant cells in heavy smokers as shown in normal cells and tissues (Napoli and Race, 1988; Wang et al., 1991) , and exert growth stimulation.
Materials and methods

Cell lines and culture conditions
Human non-small-cell lung cancer (NSCLC) cell lines including squamous cell carcinomas (Calu-1, H157, H226a), adenocarcinoma (H1792), bronchoalveolar carciRetinoid stimulation of lung carcinoma growth H Wan et al nomas (H322a, H358), and carcinoid (H292G) were purchased from the American Type Culture Collection (ATCC, Rockville, MD) or kindly provided by Dr Adi Gazdar (University of Texas Southwestern Medical Center, Dallas, TX). Fetal bovine serum (FBS) was delipidized by mixing vigorously 1.5 volumes of serum with 1 volume of Seroclear 1 (Calbiochem, La Jolla, CA) for 30 s followed by a 10 min contrifugation at 1000 g to separate the phases and collecting the serum fraction. Retinol was present in the FBS at a concentration of about 0.7 mM but could not be detected in delipidized FBS by high performance liquid chromatography (HPLC) analysis conducted according to the method of Peng et al. (1987) . all-trans-Retinoid acid (ATRA) and 13-cis-RA were not detected by HPLC in delipidized FBA.
The cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% FBS. Cells were switched to medium containing either delipidized serum or serum-free medium as required. In some experiments, serum-free medium was supplemented with 0.15% bovine serum albumin either fatty acid-free or containing fatty acids (Sigma Chemical Co., St Louis, MO). All cells were incubated at 378C in a humidi®ed atmosphere of 5% CO 2 :95% air.
Retinoids
Retinol; retinal; ATRA; 13-cis-RA; 9-cis-RA; 4- (5,6,7,8-tetrahydro -5,5,8,8 -tetramethyl -2-naphthalenylcarbamoyl) benzoic acid (Am80) (Kagechika et al., 1989) and 6-(5,6,7,8 -tetrahydro -5,5,8,8 -tetramethyl-2-naphthalenyl )-2-naphthalenecarboxylic acid (TTNN) (Dawson et al., 1983) were provided by Dr Werner Bollag (F Homann-La Roche, Basel, Switzerland); 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437) (Bernard et al., 1992) ; (E)-4-{2-[3-(1-adamantyl)-4-hydroxyphenyl] propenyl}benzoic acid (CD2325); (E)-7-[3-(1-adamantyl)-4-methoxyphenyl]-3-methylocta-2,4,6-trienoic acid (CD2366) were provided by Drs Braham Shroot and Uwe Reichert (CIRD/Galderma, Valbonne, France); N-(4-hydroxyphenyl)retinamide (4HPR) was provided by Dr Ronald Lubet (Chemoprevention Branch, National Cancer Institute, Bethesda, MD); 6-(3-hydroxymethyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl )-2-naphthalenecarboxylic acid (SR11363) (Dawson et al., 1995a); 6-(5,6,7,8-tetrahydro -3,5,5,8,8-pentamethyl-2-naphthalenyl )-2-naphthalenecarboxylic acid (SR3985) (Dawson et al., 1983), 4-[2-methyl -1-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) propenyl] benzoic acid (SR11217) (Lehmann et al., 1992) ; 2 -(4 -carboxyphenyl) -2 - (5,6,7,8, -tetrahydro -5,5,8, 8 -tetramethyl -2 -naphthalenyl) -1,3 -dithiolane (SR11234) (Lehmann et al., 1992; Dawson et al., 1995b) ; and 2-(4-carboxyphenyl) -2 -(3,4 -dihydro -4,4-dimethyl-2H-1-benzopyran-6-yl)-1,3-dithiane (SR11238) were synthesized as reported. 5, 5, 8, 6, 7, ethenyl]benzoic acid (LG1-069) (Boehm et al., 1994) was provided by Dr Richard A Heyman (Ligand Pharmaceuticals, San Diego, CA). Retinoids were dissolved in dimethylsulfoxide (DMSO) at a concentration of 10 72 M and stored in the dark at 720 8C under N 2 . Stock solutions were diluted to the appropriate ®nal concentrations in growth medium. Control cultures received the same amount of DMSO (0.01%) as retinoid-treated cultures did.
Determination of growth response to retinoid treatment
Cells were seeded at 2610 4 cells in each well of a 12-well plate in 10% delipidized FBS in DMEM/F12 medium. After 36 h, the medium was replaced with fresh medium with or without delipidized serum containing DMSO (control) or the indicated concentration of retinoids in DMSO. Medium was replaced by fresh medium on day 3. On day 5, cells were detached after a brief incubation with 2 mM ethylenediaminetetratacetic acid and 0.25% trypsin in calcium-free and magnesium-free phosphate-buered saline, pH 7.2, and counted using an electronic cell counter. The number of cells in control cultures on day 5 was set as 100%. The results are presented as the mean+s.d. of six replicate wells for each experimental group.
Northern blot analysis of retinoic acid receptor transcripts
Plasmids containing RARa, RARb, and RARg cDNAs were provided by Dr Pierre Chambon (IGBMC, Illkirch, Strasbourg, France), and labeled probes were prepared as described elsewhere (Zou et al., 1994) . The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe was synthesized from a 1.3 kb fragment spanning the entire open reading frame of cDNA cloned from chicken muscle (Dugaiczyk et al., 1983) . Total RNA isolated from cells by the method described by Chirgwin et al. (1979) was fractionated on 1.2% formaldehyde agarose gel (30 mg/ lane), stained with ethidium bromide and transferred to Hybond N + membranes by capillary transfer. Dierent probes labeled with 32 P with random hexanucleotides as primers were used for hybridization in 50% formamide, 5 6 saline sodium citrate (SSC), 1 6 Denhardt's solution (0.02% Ficoll 400, 0.02% polyvinylpyrrolidone and 0.02% bovine serum albumin), 0.5% sodium dodecylsulfate (SDS) and 0.1 mg/ml salmon sperm DNA. Blots were washed in 0.1 6 SSC and 0.1% SDS for 1 h at 608C and then exposed to Kodak X-OMAT ®lm with intensifying screens for autoradiography at 7808C for 1 to 4 days. Band sizes were determined by comparison to an RNA ladder (Bethesda Research Laboratories, Bethesda, MD).
Gel-shift and supershift assays
The preparation of nuclear extracts and gel-shift assays were performed as described previously by Oridate et al. (1996) . The synthetic oligonucleotide indicated below with the respective consensus sequences underlined were labeled with g-32 P-ATP (4000 Ci/mol) using T4 polynucleotide kinase: the RARE present in the RARb2 gene (de The et al., 1990) 5'-TCGAGGGTAGGGTTCACCGAAAGTT-CACTCG-3'; and the TPA response element TRE 2 5' -CTTCGTGACTCAGCGGGATCCTTCGTGACTCAG CGG-3'. Nuclear extracts were pre-incubated with 2 mg of poly (dI-dC) . poly (dI-dC) for 15 min at 48C and then incubated with labeled DNA (approx 10 000 c.p.m.) for 15 min at 48C in the presence of 10 mM Tris-HCl, pH 7.5, 10 mM KCl, 1 mM EDTA, 1 mM DTT, 5 mM MgCl 2 , 20% glycerol. The reaction mixture (20 ml) was electrophoresed in a 5% polyacrylamide gel containing 25 mM Tris HCl, pH 8.5, 192 mM glycine, 1 mM EDTA. For the supershift analysis, 0.5 ml aliquots of receptor-speci®c monoclonal antibodies (Rochette-Egly et al., 1991; provided by Dr Pierre Chambon (IGBMC, Illkirch, Strasbourg, France) were added to the reaction mixture.
Transient expression and luciferase assays
The AP-1-TK-LUC reporter plasmid contained the luciferase gene controlled by a promoter, which includes a classic AP-1 binding site (TGAGTCA) and connected to the herpes simplex virus (HSV) thymidine kinase (TK) promoter. The same plasmid with a mutation in the AP-1 binding site (TGCTCCA) and a plasmid containing only TK-LUC were used as controls. These plasmids were provided by Dr Jonathan Kurie (M.D. Anderson cancer center, Houston, TX). The (RARE) 3 -TK-LUC reporter plasmid contained three direct repeats of RARE from the P2 promoter region of the human RARb2 gene (from 759 to 733) connected to the TK promoter (provided by Dr Richard A Heyman, Ligand Pharmaceuticals, San Diego, CA). Cells were seeded at a concentration of 2.5610 5 cells per well of 6-well plates. After 24 h, cells were transfected using the lipofectamine method as suggested by the manufacturer (Gibco, Grand Island Biological Co, Grand Island, NY). Each well received 6 ml lipofectamine and 1.2 mg of plasmid DNA, which included 1 mg of plasmids containing either the RARb RARE or TRE linked to the HSV TK promoter and the luciferase (LUC) reporter gene (TK-LUC, [RARb2 RARE] 3 -TK-LUC, and AP-1-TK-LUC) and 0.2 mg of plasmid pCH110 encoding bgalactosidase (Pharmacia Biotech, Piscataway, NJ), which was used as an internal transfection eciency control. After 6 ± 12 h of transfection, cells were cultured in medium containing either 10% delipidized serum or no serum and the indicated concentration of retinoids in DMSO or DMSO alone for 14 ± 18 h. Cells were then harvested for measurement of b-gal activity and luciferase activity by using a luciferase assay system and protocol from Promega (Technical Manual #TM033, Madison, WI) and a luminometer (Lumat). Triplicate wells were used for each experimental group. Relative luciferase activity was normalized to the b-gal activity to account for transfection eciency.
